HOME >> BIOLOGY >> NEWS
Rethinking anti-oxidants

A leading researcher at the University of New South Wales (UNSW) points out that there is little convincing evidence that dietary antioxidant supplements such as vitamin E prevent heart disease, despite claims to the contrary.

Instead there has been a surprise finding, which relates to a synthetic antioxidant, the drug Probucol, which is no longer prescribed in Australia.

"There has been a lot of hype which suggested that antioxidant vitamin supplements had a beneficial outcome for cardiovascular disease. There is no good scientific support for the notion that people who suffer from atherosclerosis, or who are at elevated risk of heart disease, gain benefit by supplements of vitamin E," said Professor Roland Stocker, from the Centre for Vascular Research at UNSW, who will present his research at the ISTH Congress in Sydney today.

Stocker reported, "Our research is now leading towards the development of a new drug, based on Probucol. Probucol was previously used to reduce so-called "bad" cholesterol for those with heart disease, but it also had side effects, such as reducing "good" cholesterol and possibly inducing an irregular heartbeat.

This new compound, which has a similar structure to probucol, is very effective in protecting against atherosclerosis (the principal cause of coronary heart disease) in animal models but doesn't have the same side effects"

He went onto say, "We have shown that this novel probucol-analog induces a pathway in the vessel wall which is both anti-oxidative and anti-inflammatory. The early signs are that it provides strong protection for blood vessel walls. We are now progressing these studies further with a pharmaceutical company."

"This compound potentially represents a new approach for treating people with or at risk of heart disease at the source of the problem in the vessel wall. Vitamin E is not depleted or deficient in people with heart disease. It is in my view, a nave ide
'"/>

Contact: Sarah Meachem
Sarah.Meachem@phimr.monash.edu.au
61-412-640-774
Research Australia
9-Aug-2005


Page: 1 2

Related biology news :

1. Rethinking new therapies for Crohns disease at U.Va.

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rethinking anti oxidants

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: